Corvus Pharmaceuticals Inc.

Last updated September 27, 2026

Favorite this organization

Organization details

Legal name: Corvus Pharmaceuticals Inc.
Ownership: Public
Status: Active
Sector (GICS): Health Care
SIC code: 2834 — Pharmaceutical Preparations
Jurisdiction of incorporation: Delaware
Headquarters city: South SAN Francisco
Headquarters state / province: California
Headquarters country: United States
Fiscal year end: December
Ticker symbol: CRVS
Primary stock exchange: Nasdaq

Identifiers

SEC CIK: 0001626971
EIN: 46-4670809

Board of directors

Follow this board

Andrew C. Chan · Director
Since 2026
David Scott Moore · Director
Since 2025
Den Broek Richard Van · Director
Since 2025
Edith P. Mitchell · Director
Since 2023
Ian T. Clark · Director Overboarded
Since 2023
Linda Grais · Director
Since 2023
Peter A. Thompson · Director Overboarded
Since 2023
Richard A. Miller M.D. · Director · President and CEO
Since 2023
Scott W. Morrison · Director Overboarded
Since 2023
Terry P. Gould · Director
Since 2023

Chief executives

Richard A. Miller M.D. · President and CEO

Dates unknown

Director election results

Annual meeting of June 11, 2026. Support is votes for as a share of votes for and against (or withheld). Below 80% is a clear protest.

Linda Grais

87.2%
Richard A. Miller M.D.

95.6%

Board connections

6 of this board's directors also sit on 19 other boards. 18 are in the same sector.

Shared director Other board Same sector +3 more in the list below

ARS Pharmaceuticals Inc. Same sector
via Peter A. Thompson
Aspen Neuroscience Inc. Same sector
via Peter A. Thompson
BioMarin Pharmaceutical Inc. Same sector
via Ian T. Clark
Bolt Biotherapeutics Inc. Same sector
via Richard A. Miller M.D.
Edgewise Therapeutics Inc. Same sector
via Peter A. Thompson
GoodRx Holdings Inc.
via Ian T. Clark
Guardant Health Inc. Same sector
via Ian T. Clark
ICON plc Same sector
via Linda Grais
IDEAYA Biosciences Inc. Same sector
via Scott W. Morrison
Kyverna Therapeutics Inc. Same sector
via Ian T. Clark
Olema Pharmaceuticals Inc. Same sector
via Ian T. Clark
Oruka Therapeutics Inc. Same sector
via Linda Grais
Pulse Biosciences Inc Same sector
via Den Broek Richard Van
Sionna Therapeutics Inc. Same sector
via Peter A. Thompson
Takeda Pharmaceutical Company Limited Same sector
via Ian T. Clark
Tarsus Pharmaceuticals Inc. Same sector
via Scott W. Morrison
Tectonic Therapeutic Inc. Same sector
via Ian T. Clark
Vera Therapeutics Inc. Same sector
via Scott W. Morrison
Zai Lab Limited Same sector
via Scott W. Morrison

Insider trades

All notable trades →

From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.

Bought, last 12 months: $333,654; 3 purchases by 2 insiders
Sold, last 12 months: $0; 0 sales by 0 insiders

Date	Insider	Transaction	Shares	Price	Value
Jun 11, 2026	David Scott Moore Director	Open-market purchase	+21,700	$11.53	$250,201
May 18, 2026	Richard A. Miller M.D. Director, Officer (President and CEO)	Open-market purchase	+5,000	$12.05	$60,250
May 18, 2026	Richard A. Miller M.D. Director, Officer (President and CEO)	Open-market purchase	+1,932	$12.01	$23,203
Jan 28, 2026	Peter A. Thompson Director, 10% owner	Option exercise	+30,000	$15.00	$450,000
Jan 28, 2026	Peter A. Thompson Director, 10% owner	Option exercise	+15,000	$9.70	$145,500
Jan 28, 2026	Peter A. Thompson Director, 10% owner	Option exercise	+15,000	$12.50	$187,500
Jan 28, 2026	Peter A. Thompson Director, 10% owner	Option exercise	+15,000	$3.61	$54,150
Jan 28, 2026	Peter A. Thompson Director, 10% owner	Option exercise	+15,000	$2.00	$30,000
Jan 28, 2026	Peter A. Thompson Director, 10% owner	Option exercise	+15,000	$3.27	$49,050
Jan 28, 2026	Peter A. Thompson Director, 10% owner	Option exercise	+15,000	$2.74	$41,100
Jan 28, 2026	Peter A. Thompson Director, 10% owner	Option exercise	+15,000	$2.60	$39,000
Jan 28, 2026	Peter A. Thompson Director, 10% owner	Option exercise	+15,000	$0.99	$14,850
Jan 28, 2026	Peter A. Thompson Director, 10% owner	Option exercise	+15,000	$0.97	$14,550
Jan 28, 2026	Peter A. Thompson Director, 10% owner	Option exercise	+15,000	$2.49	$37,350
Jan 28, 2026	Peter A. Thompson Director, 10% owner	Option exercise	+15,000	$1.64	$24,600

Peers

Compare boards

Organizations in the same sector, closest in location and size first.

3M Company NYSE: MMM · ST Paul, United States Organization ABVC BioPharma Inc. Nasdaq: ABVC · Fremont, United States Organization ACADIA Pharmaceuticals Inc. Nasdaq: ACAD · SAN Diego, United States Organization ADMA Biologics Inc Nasdaq: ADMA · Ramsey, United States Organization

Questions about Corvus Pharmaceuticals Inc.

Who is the CEO of Corvus Pharmaceuticals Inc.?

Richard A. Miller M.D. is Corvus Pharmaceuticals Inc.'s President and CEO.

How many directors are on Corvus Pharmaceuticals Inc.'s board?

Corvus Pharmaceuticals Inc.'s board has 10 directors: Andrew C. Chan, David Scott Moore, Den Broek Richard Van, Edith P. Mitchell, Ian T. Clark, Linda Grais, Peter A. Thompson, Richard A. Miller M.D., Scott W. Morrison and Terry P. Gould.

Are Corvus Pharmaceuticals Inc. insiders buying or selling shares?

Over the last 12 months, Corvus Pharmaceuticals Inc. insiders bought $333,654 of shares in 3 purchases and made no open-market sales on the open market, as reported to the SEC on Forms 4 and 5.

How is Corvus Pharmaceuticals Inc. connected to…? → Spot something wrong? Report a correction

Embed this board on your site

Paste this where the board should appear. It always shows the current directors and links back here.

<div data-bod-board="corvus-pharmaceuticals-inc"></div>
<script src="https://boardofdirectors.review/embed.js" async></script>

Reviews (0)

No reviews yet. Be the first to write one.